Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RN1101 in Relapsed/Refractory B-cell or Plasma Cell Malignancies
NCT06976437Phase 1Recruiting
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RN1101 in B cell lymphoma, multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (B-ALL). Primary endpoint: Incidence and severity of adverse events up to 24 weeks. Started May 2025; status: recruiting.
02
Drugs
RN1101
03
Conditions
B cell lymphomamultiple myeloma (MM)B-cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06976437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06976437.